IL6ST — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL22261830	1.00	7/20
SCHEMBL22261831	1.00	7/20
SCHEMBL20943427	0.55	6/20
SCHEMBL20943428	0.55	6/20
SCHEMBL18384293	0.68	5/20
SCHEMBL18384326	0.68	5/20
SCHEMBL18391412	0.68	5/20
SCHEMBL18391413	0.68	5/20
SCHEMBL21153766	0.67	5/20
SCHEMBL21154125	0.67	5/20
SCHEMBL9970272	0.66	5/20
SCHEMBL14523671	0.66	5/20
SCHEMBL6158388	0.65	5/20
SCHEMBL6159324	0.65	5/20
SCHEMBL7413739	0.65	5/20
SCHEMBL8209628	0.65	5/20
SCHEMBL8209630	0.65	5/20
SCHEMBL8211443	0.65	5/20
SCHEMBL8211445	0.65	5/20
SCHEMBL8219400	0.65	5/20

Clinical trials — most relevant to IL6ST by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)	PHASE3	COMPLETED
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis	PHASE3	NOT_YET_RECRUITING
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)	PHASE2	RECRUITING
IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest	PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Ruxolitinib in Estrogen Receptor Positive Breast Cancer	PHASE2	COMPLETED
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP	PHASE2	COMPLETED
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19	PHASE2	COMPLETED
Colchicine and Inflammation in Hemodialysis Patients	PHASE2	UNKNOWN
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy	PHASE2	COMPLETED
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	PHASE2	COMPLETED
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation	PHASE1	RECRUITING
Clinical Study of Single Dose IL-6R mAb Injection in RA Patients	PHASE1	COMPLETED
Intraperitoneal Local Anaesthetic in Colonic Surgery	PHASE1	COMPLETED
Short-Term Application of Tocilizumab Following Myocardial Infarction	nan	COMPLETED
Investigation of Inflammatory Parameters in a Perioperative Closed-meshed Standard Progress in CPB Patients	nan	COMPLETED
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis	nan	UNKNOWN
Periduroscopy: Correlation Between the Outcome of Procedure and Histological-biochemical, Neuroinflammation and Genetic Factors.	nan	UNKNOWN
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients	nan	RECRUITING
Study of CRP, Ferritine and D-Dimer in Covid-19 Patients Admitted To Respiratory ICU in Assuit University Hospitals	nan	UNKNOWN
Effects of Spinal Manipulative Treatment on Inflammatory Markers in Low Back Pain Patients	nan	COMPLETED
Aetiology And Outcome Of Children With Thrombocytosis Admitted to Assiut University Children Hospital	nan	UNKNOWN
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome	nan	COMPLETED
Evaluation of Salivary Biomarker Levels in Individuals With Different Periodontal Conditions	nan	COMPLETED
Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45	nan	WITHDRAWN
Palmitoylethanolamide in Ulcerative Colitis	nan	NOT_YET_RECRUITING
Hemoperfusion With Efferon CT for the Treatment of Patients With Severe Psoriasis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IL6ST binder may also engage these)

Protein	Name	Similarity
P40190	—	0.999	P40190 →
Q00560	—	0.997	Q00560 →
Q8NI17	—	0.977	Q8NI17 →
Q01344	—	0.977	Q01344 →
P30931	—	0.975	P30931 →
P78552	—	0.974	P78552 →
Q63621	—	0.974	Q63621 →
Q02092	—	0.974	Q02092 →
F3	Tissue factor	0.973	landscape →
P21183	—	0.973	P21183 →
Q99650	—	0.972	Q99650 →
Q90369	—	0.972	Q90369 →
P38484	—	0.972	P38484 →
Q61730	—	0.972	Q61730 →
P33005	—	0.971	P33005 →
P24055	—	0.971	P24055 →
O46600	—	0.971	O46600 →
Q9NPH3	—	0.971	Q9NPH3 →
Q90375	—	0.971	Q90375 →
Q5XNR9	—	0.971	Q5XNR9 →
O95727	—	0.971	O95727 →
Q9TU69	—	0.970	Q9TU69 →
O09030	—	0.970	O09030 →
Q5VV43	—	0.970	Q5VV43 →
P59822	—	0.970	P59822 →
P19756	—	0.970	P19756 →
IL1R1	Interleukin-1 receptor type 1	0.970	landscape →
Q28575	—	0.969	Q28575 →
P26951	—	0.968	P26951 →
P16310	—	0.967	P16310 →